Lanean...
Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors
Immune checkpoint inhibitors are novel biologic agents to treat cancer by inhibiting the regulatory interactions that limit T cell cytotoxicity to tumours. Current agents target either CTLA-4 or the PD-1/PD-L1 axis. Because checkpoints may also regulate autoreactivity, immune checkpoint inhibitor th...
Gorde:
| Argitaratua izan da: | Rheumatology (Oxford) |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Oxford University Press
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6900913/ https://ncbi.nlm.nih.gov/pubmed/31816080 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/kez308 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|